Accumulation of mutations in antibody and CD8 T cell epitopes in a B cell depleted lymphoma patient with chronic SARS-CoV-2 infection

在患有慢性SARS-CoV-2感染的B细胞耗竭淋巴瘤患者中,抗体和CD8 T细胞表位发生突变积累。

阅读:2
作者:Elham Khatamzas # ,Markus H Antwerpen #,Alexandra Rehn,Alexander Graf,Johannes Christian Hellmuth,Alexandra Hollaus,Anne-Wiebe Mohr,Erik Gaitzsch,Tobias Weiglein,Enrico Georgi,Clemens Scherer,Stephanie-Susanne Stecher,Stefanie Gruetzner,Helmut Blum,Stefan Krebs,Anna Reischer,Alexandra Leutbecher,Marion Subklewe,Andrea Dick,Sabine Zange,Philipp Girl,Katharina Müller,Oliver Weigert,Karl-Peter Hopfner,Hans-Joachim Stemmler,Michael von Bergwelt-Baildon ,Oliver T Keppler ,Roman Wölfel,Maximilian Muenchhoff # ,Andreas Moosmann #

Abstract

Antibodies against the spike protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) can drive adaptive evolution in immunocompromised patients with chronic infection. Here we longitudinally analyze SARS-CoV-2 sequences in a B cell-depleted, lymphoma patient with chronic, ultimately fatal infection, and identify three mutations in the spike protein that dampen convalescent plasma-mediated neutralization of SARS-CoV-2. Additionally, four mutations emerge in non-spike regions encoding three CD8 T cell epitopes, including one nucleoprotein epitope affected by two mutations. Recognition of each mutant peptide by CD8 T cells from convalescent donors is reduced compared to its ancestral peptide, with additive effects resulting from double mutations. Querying public SARS-CoV-2 sequences shows that these mutations have independently emerged as homoplasies in circulating lineages. Our data thus suggest that potential impacts of CD8 T cells on SARS-CoV-2 mutations, at least in those with humoral immunodeficiency, warrant further investigation to inform on vaccine design.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。